Clinical trial
A Phase III Randomized, Double-blind, Placebo-controlled, 2-period Crossover, Multicenter Study to Assess the Effect of Indacaterol (300 μg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00620022 is registered in ClinicalTrials.gov with Novartis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Randomized, Double-blind, Placebo-controlled, 2-period Crossover, Multicenter Study to Assess the Effect of Indacaterol (300 μg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Lead sponsor
- Novartis
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 30, 2008
- Completion date
- January 31, 2009
- Enrollment
- 90 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.
chronic obstructive pulmonary disease
Lead sponsor's other trials
Novartis, most recent start first.
+3,426 more trials See the organization page
Similar trials
Same condition (Pulmonary Disease, Chronic Obstructive) and phase, most recent start first.
+498 more trials See the condition page